Home › Pathology › Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

For medical students2 min readUpdated 2026-10-10

Chronic Lymphocytic Leukemia (CLL) is a hematologic malignancy characterized by the progressive accumulation of mature, small-appearing lymphocytes in the bone marrow and peripheral blood. This neoplasm shares a common biological origin with small lymphocytic lymphoma (SLL), but differs by its obligate presence of malignant cells in the bloodstream.

LeukocytosisUp to 100 × 10⁹/L and higher, with an absolute lymphocytosis exceeding 5,000 cells/µL.

Bone MarrowLymphocytes consistently comprise more than 30% of total nucleated cells in bone marrow aspirates.

AgePeak incidence is 50–60 years. Accounts for about 50% of all leukemias in individuals older than 60.

Target OrgansThe liver, spleen, and lymph nodes are almost always involved in the pathological process.

Epidemiology and Nosological Independence

Chronic lymphocytic leukemia is one of the most common hematologic malignancies in older adults. Epidemiological data show that the peak incidence occurs between the ages of 50 and 60. It is extremely rare in individuals under 40. Notably, among all leukemias diagnosed in patients older than 60, CLL accounts for approximately half of all cases.

From a pathological anatomy perspective, B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma are considered the same disease entity. The primary distinction between these two presentations lies in the anatomical site of manifestation: a diagnosis of CLL is established when malignant cells are definitively identified in the peripheral blood.

Blood Smear and Bone Marrow Findings

Because the disease originates in the bone marrow, primary pathological changes unfold there. Bone marrow examination reveals marked lymphocytosis, with lymphocytes accounting for more than 30% of all cells.

The entry of the malignant clone into the vascular bed dramatically alters the peripheral blood picture. Massive leukocytosis develops: the white blood cell count can reach enormous values of up to $100 \times 10^9$/L or even higher, accompanied by absolute lymphocytosis exceeding 5,000 cells/µL.

The cellular morphology in this disease is quite specific. The neoplastic elements are mature, nearly monomorphic small lymphocytes. Under the microscope, they feature dark, round nuclei and a very narrow rim of cytoplasm.

A classic hallmark of CLL on a blood smear is the presence of Gumprecht shadows (also known as Botkin-Gumprecht bodies). These appear as amorphous, smudged smears representing destroyed cells. The phenomenon occurs because malignant lymphocytes have decreased mechanical fragility and rupture easily during the physical preparation of the blood smear.

Pathogenesis, Immune Status, and Clinical Features

The progression of chronic lymphocytic leukemia is accompanied by systemic involvement. Pathological cells disseminate from the bone marrow via the bloodstream, with the liver, spleen, and lymph nodes serving as virtually constant target organs.

The clinical presentation is largely determined by alterations in the patient's immune status:

Hypogammaglobulinemia: A drop in normal serum immunoglobulins (Ig) leaves the body vulnerable to infections.
Paraproteinemia: Pathological immunoglobulins produced by the neoplastic clones circulate in the blood.

As early as the initial stages, approximately 10% of patients may develop severe complications, most notably autoimmune hemolytic anemia and thrombocytopenia. In advanced stages of the disease, when neoplastic masses extensively replace normal hematopoietic tissue, pancytopenia—a critical reduction in all blood cell lineages—inevitably develops.

Mnemonic

To remember the primary morphological marker of CLL, imagine that the malignant lymphocytes are so fragile that they burst when a drop of blood is smeared across the glass slide, leaving only smudged ghosts of cells—Gumprecht shadows.

Frequently asked questions

Which cytogenetic mutations and chromosomal aberrations are most commonly detected in chronic lymphocytic leukemia?

In chronic lymphocytic leukemia, the primary cytogenetic marker is the 17p deletion, along with TP53 gene mutations.

17p deletion (del(17p)) — a negative prognostic marker that guides treatment selection.
TP53 gene mutations (TP53) — cause therapy refractoriness due to the loss of gene function. They can occur either in combination with the deletion or as isolated mutations.

The threshold defining the presence of a mutation is typically an allele burden exceeding 10%.

What is the main difference between chronic lymphocytic leukemia and small lymphocytic lymphoma?

These neoplasms are virtually identical in cellular composition. The key distinction is that in CLL, a high number of malignant cells are identified in the peripheral blood.

What are Gumprecht shadows?

These are specific smudged, irregular amorphous remnants of destroyed cells. They appear on blood smears because malignant lymphocytes rupture easily upon mechanical stress.

Why is the immune status impaired in this disease?

The malignant cell clone crowds out normal lymphocytes, leading to decreased serum immunoglobulin levels. Additionally, the tumor cells themselves may produce defective immunoglobulins, causing paraproteinemia.

What complications are characteristic of early and late stages?

About 10% of patients develop autoimmune hemolytic anemia and thrombocytopenia in early stages. In late stages, pancytopenia occurs due to total bone marrow failure.

Go deeper

Mechanisms of autoimmune hemolytic anemia and thrombocytopenia development in CLL.
Pathogenesis of pancytopenia in advanced stages of the disease.
Morphological changes in the liver, spleen, and lymph nodes during leukemic infiltration.
The nature of paraproteinemia: synthesis of pathological immunoglobulins by neoplastic clones.